Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
FUTURA/OASIS-8 Trial Group; Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, López-Sendón JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. FUTURA/OASIS-8 Trial Group, et al. Among authors: chrolavicius s. JAMA. 2010 Sep 22;304(12):1339-49. doi: 10.1001/jama.2010.1320. Epub 2010 Aug 31. JAMA. 2010. PMID: 20805623 Clinical Trial.
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Yusuf S, et al. Among authors: chrolavicius s. JAMA. 2006 Apr 5;295(13):1519-30. doi: 10.1001/jama.295.13.joc60038. Epub 2006 Mar 14. JAMA. 2006. PMID: 16537725 Clinical Trial.
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
Steg PG, Mehta S, Jolly S, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Chrolavicius S, Rao SV, Granger CB, Pogue J, Laing S, Yusuf S. Steg PG, et al. Among authors: chrolavicius s. Am Heart J. 2010 Dec;160(6):1029-34, 1034.e1. doi: 10.1016/j.ahj.2010.07.037. Am Heart J. 2010. PMID: 21146654 Clinical Trial.
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
MICHELANGELO OASIS 5 Steering Committee; Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA. MICHELANGELO OASIS 5 Steering Committee, et al. Among authors: chrolavicius s. Am Heart J. 2005 Dec;150(6):1107. doi: 10.1016/j.ahj.2005.09.025. Am Heart J. 2005. PMID: 16338245 Clinical Trial.
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. Among authors: chrolavicius s. N Engl J Med. 2006 Apr 6;354(14):1464-76. doi: 10.1056/NEJMoa055443. Epub 2006 Mar 14. N Engl J Med. 2006. PMID: 16537663 Free article. Clinical Trial.
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S; OASIS 5 Investigators. Fox KA, et al. Among authors: chrolavicius s. Ann Intern Med. 2007 Sep 4;147(5):304-10. doi: 10.7326/0003-4819-147-5-200709040-00005. Ann Intern Med. 2007. PMID: 17785485 Clinical Trial.
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S. Mehta SR, et al. Among authors: chrolavicius s. J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51. doi: 10.1016/j.jacc.2007.07.042. Epub 2007 Oct 15. J Am Coll Cardiol. 2007. PMID: 17964037 Free article. Clinical Trial.
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, Fox KA, Granger CB, Mehta SR, Pais P, Peters RJ, Xavier D, Zhu J, Yusuf S; OASIS-6 Investigators. Oldgren J, et al. Among authors: chrolavicius s. Eur Heart J. 2008 Feb;29(3):315-23. doi: 10.1093/eurheartj/ehm578. Epub 2007 Dec 15. Eur Heart J. 2008. PMID: 18084015 Clinical Trial.
48 results